ALZN - CIK 0001677077
Alzamend Neuro, Inc. trades as ALZN. This page tracks Alzamend Neuro, Inc. through 374 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-04-17 |
| Insider trade | 4 | 2026-04-16 |
| Major company event | 8-K | 2026-03-20 |
| Quarterly report | 10-Q | 2026-03-11 |
| Prospectus supplement | 424B5 | 2026-03-06 |
| Major company event | 8-K | 2026-03-06 |
| Proxy materials | DEFA14A | 2026-02-26 |
| Proxy statement | DEF 14A | 2026-02-26 |
The largest companies sharing Alzamend Neuro, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Alzamend Neuro, Inc. reported a net loss of $4.51M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.